Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease. The IBD ...

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

as well as the approval of Omvoh for moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY) has seen impressive growth in recent years, largely due to the success of its ...

A BBC Morning Live GP has issued an urgent warning to anyone taking antibiotics. Dr Punam Krishan said people need to be careful when they are prescribed the medication. Taking antibiotics incorrectly ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new study has found. This study, conducted by researchers from the University ...